How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/secondarily-generalized-seizures.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Secondarily generalized seizures — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Secondarily generalized seizures (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Secondarily generalized seizures, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Fycompa	PERAMPANEL	Catalyst Pharms	Noncompetitive AMPA Glutamate Receptor Antagonist [EPC]	Glutamate receptor ionotropic AMPA		2012-01-01
Fycompa	Fycompa	Eisai Inc.		Glutamate receptor ionotropic AMPA

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Catalyst Pharms · 1 drug in Secondarily generalized seizures
Eisai Inc. · 1 drug in Secondarily generalized seizures

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Secondarily generalized seizures:

Cite this brief

Drug Landscape (2026). Secondarily generalized seizures — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/secondarily-generalized-seizures. Accessed 2026-06-10.

Secondarily generalized seizures full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing